Beauty Health Co. Files 8-K on Director Changes and Compensation
Ticker: SKIN · Form: 8-K · Filed: Nov 3, 2025 · CIK: 1818093
| Field | Detail |
|---|---|
| Company | Beauty Health Co (SKIN) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, filing
TL;DR
Beauty Health Co. 8-K: Director changes, exec comp, and financial updates filed Oct 30, 2025.
AI Summary
On October 30, 2025, The Beauty Health Company filed an 8-K report detailing changes in its board of directors and executive compensation. The filing also includes information on financial statements and exhibits, as well as a Regulation FD disclosure. The company, formerly Vesper Healthcare Acquisition Corp., is incorporated in Delaware and headquartered in Long Beach, California.
Why It Matters
This filing provides insight into potential shifts in the company's leadership and financial arrangements, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of corporate events and does not indicate immediate financial distress or significant operational changes.
Key Numbers
- 001-39565 — SEC File Number (Identifies the company's filing with the SEC)
- 85-1908962 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- The Beauty Health Company (company) — Registrant
- Vesper Healthcare Acquisition Corp. (company) — Former company name
- October 30, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Long Beach, CA (location) — Principal executive office address
FAQ
What specific changes were made to the board of directors?
The filing indicates changes in directors and the election of new directors, but the specific names and details of these changes are not provided in the excerpt.
What are the key aspects of the compensatory arrangements of certain officers?
The filing mentions compensatory arrangements for certain officers, but the specific details of these arrangements are not elaborated upon in the provided text.
What is the significance of the Regulation FD Disclosure?
A Regulation FD Disclosure ensures that material non-public information is broadly disseminated to the public, preventing selective disclosure.
What financial statements and exhibits are included in this filing?
The filing states that Financial Statements and Exhibits are included, but the specific content of these documents is not detailed in the excerpt.
When did The Beauty Health Company change its name from Vesper Healthcare Acquisition Corp.?
The date of the name change from Vesper Healthcare Acquisition Corp. to The Beauty Health Company was July 14, 2020.
Filing Stats: 1,141 words · 5 min read · ~4 pages · Grade level 10.5 · Accepted 2025-11-03 16:10:36
Key Financial Figures
- $0.0001 — tered Class A Common Stock, par value $0.0001 per share SKIN The Nasdaq Capital Marke
Filing Documents
- skin-20251030.htm (8-K) — 36KB
- ex991-beautyhealthpschaiso.htm (EX-99.1) — 7KB
- image_0a.jpg (GRAPHIC) — 23KB
- 0001628280-25-048229.txt ( ) — 227KB
- skin-20251030.xsd (EX-101.SCH) — 2KB
- skin-20251030_def.xml (EX-101.DEF) — 15KB
- skin-20251030_lab.xml (EX-101.LAB) — 26KB
- skin-20251030_pre.xml (EX-101.PRE) — 16KB
- skin-20251030_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On November 3, 2025, the Company issued a press release announcing the appointment of Dr. Schaison as a director of the Board. A copy of this press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Exhibit 99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements. The information set forth under Item 7.01 of this Current Report on Form 8-K (this "Current Report"), including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated November 3, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: November 3, 2025 The Beauty Health Company By: /s/ Michael Monahan Name: Michael Monahan Title: Chief Financial Officer